Clindamycin Supply Overview for Prescribers

Clindamycin phosphate injection has been in recurrent shortage since 2010, with supply disruptions intensifying significantly during 2023-2025. As of early 2026, the injectable formulation remains listed in active shortage by both the ASHP Drug Shortage Resource Center and the FDA Drug Shortage Database. Multiple manufacturers — including Pfizer (brand Cleocin), Hikma, Fresenius Kabi, and Hospira — have reported intermittent supply constraints affecting vials and premixed IV bags.

Oral Clindamycin hydrochloride capsules (75mg, 150mg, 300mg) and oral solution remain generally available through standard distribution channels, though providers should be aware that intermittent spot shortages at individual retail pharmacies have been reported throughout 2025-2026. Topical and vaginal formulations are not currently affected.

Timeline of Injectable Clindamycin Shortages

Understanding the history of this shortage is important for anticipating future supply dynamics:

• 2010-2015: Initial injectable shortages reported, primarily driven by manufacturing quality issues at sterile injectable facilities. Shortages were episodic and typically resolved within months.
• 2016-2019: Relative supply stability, though the overall sterile injectable market remained fragile due to manufacturing concentration among a small number of producers.
• 2020-2022: COVID-19 pandemic disrupted pharmaceutical supply chains broadly. Clindamycin injection experienced sporadic availability issues as hospital demand fluctuated.
• 2023-2025: Shortages intensified due to a combination of manufacturing delays, API (active pharmaceutical ingredient) sourcing challenges, and increased demand. Multiple manufacturers reported allocation-based distribution, limiting quantities available to individual facilities.
• 2026 (current): The injectable shortage persists. While some manufacturers have resumed partial production, supply has not yet fully recovered to meet demand.

Prescribing Implications

The ongoing shortage has several practical implications for clinical practice:

• IV-to-oral conversion: Where clinically appropriate, consider early transition from IV to oral Clindamycin. Oral Clindamycin has excellent bioavailability (approximately 90%), making it suitable for step-down therapy in many indications including skin and soft tissue infections, osteomyelitis (after initial IV loading), and pulmonary infections.
• Formulary substitution: Hospital pharmacy and therapeutics committees should have pre-approved alternatives in place. For empiric coverage of gram-positive and anaerobic organisms, consider substitution protocols based on indication and local antibiogram data.
• Outpatient considerations: When prescribing oral Clindamycin for outpatient use, be aware that patients may encounter spot shortages at their pharmacy. Proactively checking availability using tools like Medfinder before sending the prescription can reduce patient frustration and treatment delays.
• C. difficile risk stratification: Given Clindamycin's boxed warning for C. difficile-associated diarrhea, the current shortage may present an opportunity to reassess prescribing patterns and favor lower-risk alternatives in appropriate patients, particularly the elderly or those with prior CDAD history.

Cost and Access Data for Patient Conversations

Understanding the cost landscape helps providers counsel patients effectively and anticipate adherence barriers:

• Generic oral Clindamycin with discount card: $9-$30 (varies by pharmacy and quantity)
• Generic oral Clindamycin at retail (no discount): $106-$109
• Brand Cleocin: $400+ (rarely dispensed)
• Insurance tier: Tier 1 preferred generic on most formularies; typical copay $0-$15; prior authorization generally not required
• Patient assistance: No active manufacturer savings programs for generic Clindamycin. NeedyMeds, RxAssist, and RxHope maintain databases of assistance programs. Prescription Hope offers access for approximately $50/month for qualifying patients.

The tenfold price difference between discount and retail pricing ($9 vs. $106) underscores the importance of directing patients to pricing comparison tools, particularly those without insurance coverage.

Tools for Your Practice

Several resources can help providers and their care teams navigate the Clindamycin shortage:

• Medfinder Provider Portal: Real-time pharmacy stock checking and price comparison. Allows staff to verify medication availability before sending prescriptions, reducing callbacks and patient delays. The provider portal includes features designed for clinical workflows.
• FDA Drug Shortage Database: Official federal tracking of current and resolved shortages, including manufacturer-specific estimated resupply dates for injectable Clindamycin.
• ASHP Drug Shortage Resource Center: Clinical guidance documents, shortage duration estimates, and therapeutic substitution recommendations developed by pharmacy specialists.
• State prescription drug monitoring programs: While Clindamycin is not a controlled substance, some state programs provide supply visibility data that may be useful for tracking local availability trends.

Evidence-Based Alternatives by Indication

When Clindamycin is unavailable or contraindicated, consider the following alternatives based on clinical indication:

• Skin and soft tissue infections (SSTI): Doxycycline or trimethoprim-sulfamethoxazole (TMP-SMX) for MRSA coverage; cephalexin for MSSA. For severe infections requiring IV therapy, vancomycin or daptomycin may be substituted for parenteral Clindamycin.
• Anaerobic infections: Metronidazole remains the primary alternative with excellent anaerobic coverage. Consider combination therapy if broader gram-positive coverage is needed.
• Respiratory infections: Azithromycin or Erythromycin provide macrolide coverage as alternatives, though spectrum differences should be considered. Check local antibiogram data for resistance patterns.
• Bone and joint infections: Consult infectious disease for complex cases. Oral options may include Doxycycline, TMP-SMX, or fluoroquinolones depending on culture and sensitivity data.
• Bacterial vaginosis: Metronidazole (oral or vaginal) is the standard first-line alternative to Clindamycin vaginal cream.
• Acne (topical): Benzoyl peroxide combinations, topical Erythromycin, or topical Dapsone may substitute for topical Clindamycin.

For patient-facing information on alternatives and finding Clindamycin in stock, you may direct patients to our guides on Clindamycin alternatives and finding Clindamycin in stock. For patient-oriented shortage information, see our 2026 patient shortage update.